TGFB1 and breast carcinoma: TGF-β type I receptor kinase inhibitors have been developed that selectively inhibit TGF-β responses [5], including the induction of breast cancer cell migration, epithelial to mesenchymal transition, and invasion and metastasis to bone [31,32].